Taxotere is a cancer medicine used to treat the following types of cancer: - breast cancer. Taxotere can be used on its own after other treatments have failed. It can also be used with other cancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated; - non-small cell lung cancer. Taxotere can be used on its own after other treatments have failed. It can also be used with cisplatin (another cancer medicine) in patients who have not received any treatment for their cancer; - prostate cancer, when the cancer has spread to other parts of the body (metastatic). Taxotere is used with prednisone or prednisolone (anti-inflammatory medicines) when the cancer cannot be treated by greatly reducing the body's production of testosterone (castration-resistant prostate cancer). It can also be used with androgen-deprivation therapy when hormonal treatment still works (hormone-sensitive prostate cancer); - gastric adenocarcinoma (a stomach cancer) that has spread in patients who have not received any treatment for their cancer. Taxotere is used with cisplatin and fluorouracil (other cancer medicines); - head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread). Taxotere is used with cisplatin and fluorouracil. Taxotere contains the active substance docetaxel.
Therapeutic Indication
### Therapeutic indication **Breast cancer** Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: - operable node-positive breast cancer; - operable node-negative breast cancer. For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. **Non-small-cell lung cancer** Taxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy. Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition. **Prostate cancer** Taxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. **Gastric adenocarcinoma** Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. **Head and neck cancer** Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Therapeutic Area (MeSH)
ATC Code
L01CD02
ATC Item
docetaxel
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| docetaxel | N/A | 多西他赛 |
EMA Name
Taxotere
Medicine Name
Taxotere
Aliases
N/ANo risk management plan link.
